Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Intra-articular metHuIL-1ra (anakinra)
Intra-articular metHuIL-1ra · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Anakinra | EXPERIMENTAL | anakinra |
| placebo | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| Intra-articular metHuIL-1ra (anakinra) | DRUG | anakinra |
| placebo | DRUG | placebo |
Inclusion Criteria: - Diagnosed with knee OA as determined by American College of Rheumatology (ACR) criteria - Pain defined by a level of greater than 30 mm on a 100 mm Visual Analogue Scale (VAS) - No evidence of active effusion or inflammatory flare, confirmed by investigator - Must exhibit radio...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Intra-articular metHuIL-1ra is being developed for the treatment of osteoarthritis, a musculoskeletal condition. It is given by intra-articular injection, meaning directly into the joint. The clinical program has focused on osteoarthritis of the knee, and the drug remains investigational.
Intra-articular metHuIL-1ra is being developed by Amgen Inc., which trades on Nasdaq under the ticker AMGN. Amgen is the sponsor of the clinical program for this osteoarthritis candidate.
Intra-articular metHuIL-1ra is in Phase 2 development. The program includes one completed Phase 2 trial, and no trials are currently active. The drug is investigational and has not been approved for marketing.
Intra-articular metHuIL-1ra has been studied in one clinical trial, NCT00110916, titled Treatment for Patients With Osteoarthritis (OA) of the Knee. It was a completed Phase 2 trial that enrolled 165 participants, was randomized, double blind, and placebo controlled, and included adults 18 years and older.
Intra-articular metHuIL-1ra is also known as anakinra. The name anakinra refers to the same agent, and searches for intra-articular anakinra relate to this Amgen osteoarthritis program.